Do analysts recommend HVO or APTA?

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 129.01%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts clearly believe hVIVO is more favorable than Aptamer Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Aptamer Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, HVO or APTA?

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 0.96 £17.84M -£0.87 N/A Aptamer Group £1.38M 9.38 -£14.17M -£0.11 N/A

Is HVO or APTA more profitable?

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Aptamer Group -178.52% -135.35% -44.96%

Which has better earnings & valuation, DDDD or APTA?

Aptamer Group has higher revenue and earnings than 4D pharma. Aptamer Group is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 4D pharma £718K 0.00 -£31.94M -£15.40 N/A Aptamer Group £1.38M 9.38 -£14.17M -£0.11 N/A

Is DDDD or APTA more profitable?

4D pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. 4D pharma's return on equity of -89.48% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets 4D pharma N/A -89.48% -42.64% Aptamer Group -178.52% -135.35% -44.96%

Aptamer Group (APTA) Competitors

GBX 0.37 +0.02 (+6.86%)

As of 08/21/2026 09:59 AM Eastern

Compare

APTA vs. HVO, HEMO, COIL, C4XD, and DDDD

Should you buy Aptamer Group stock or one of its competitors? Aptamer Group's main competitors and comparable companies include hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), Roquefort Therapeutics (COIL), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to hVIVO?

hVIVO (LON:HVO) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

hVIVO has a beta of 1.706, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, Aptamer Group had 1 more articles in the media than hVIVO. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for hVIVO. hVIVO's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Aptamer Group	Neutral

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Aptamer Group	-178.52%	-135.35%	-44.96%

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 3.3% of Aptamer Group shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 129.01%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts clearly believe hVIVO is more favorable than Aptamer Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aptamer Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	0.96	£17.84M	-£0.87	N/A
Aptamer Group	£1.38M	9.38	-£14.17M	-£0.11	N/A

Summary

hVIVO beats Aptamer Group on 10 of the 15 factors compared between the two stocks.

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Aptamer Group (LON:APTA) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Aptamer Group has a beta of 0.899, meaning that its share price is 10% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.501, meaning that its share price is 50% more volatile than the broader market.

3.3% of Aptamer Group shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Aptamer Group had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for Hemogenyx Pharmaceuticals. Aptamer Group's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
Hemogenyx Pharmaceuticals	Neutral

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Aptamer Group. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	9.38	-£14.17M	-£0.11	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

Summary

Aptamer Group beats Hemogenyx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Aptamer Group compare to Roquefort Therapeutics?

Aptamer Group (LON:APTA) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Aptamer Group has a net margin of -178.52% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Roquefort Therapeutics	-57,057.07%	-18.71%	-15.86%

3.3% of Aptamer Group shares are owned by institutional investors. Comparatively, 1.9% of Roquefort Therapeutics shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by company insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Roquefort Therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	9.38	-£14.17M	-£0.11	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

In the previous week, Aptamer Group had 1 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for Roquefort Therapeutics. Aptamer Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
Roquefort Therapeutics	Neutral

Aptamer Group has a beta of 0.899, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, meaning that its stock price is 95% less volatile than the broader market.

Summary

Aptamer Group beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Aptamer Group compare to C4X Discovery?

Aptamer Group (LON:APTA) and C4X Discovery (LON:C4XD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

C4X Discovery has a net margin of 42.81% compared to Aptamer Group's net margin of -178.52%. C4X Discovery's return on equity of 55.38% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
C4X Discovery	42.81%	55.38%	28.04%

C4X Discovery has higher revenue and earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	9.38	-£14.17M	-£0.11	N/A
C4X Discovery	£24.68M	0.00	£10.57M	£0.04	N/A

Aptamer Group has a beta of 0.899, indicating that its stock price is 10% less volatile than the broader market. Comparatively, C4X Discovery has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

3.3% of Aptamer Group shares are held by institutional investors. Comparatively, 52.1% of C4X Discovery shares are held by institutional investors. 7.3% of Aptamer Group shares are held by company insiders. Comparatively, 27.1% of C4X Discovery shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Aptamer Group had 1 more articles in the media than C4X Discovery. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for C4X Discovery. Aptamer Group's average media sentiment score of 0.00 equaled C4X Discovery'saverage media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
C4X Discovery	Neutral

Summary

C4X Discovery beats Aptamer Group on 9 of the 11 factors compared between the two stocks.

How does Aptamer Group compare to 4D pharma?

4D pharma (LON:DDDD) and Aptamer Group (LON:APTA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

In the previous week, Aptamer Group had 1 more articles in the media than 4D pharma. MarketBeat recorded 1 mentions for Aptamer Group and 0 mentions for 4D pharma. 4D pharma's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
4D pharma	Neutral
Aptamer Group	Neutral

4D pharma has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.899, meaning that its share price is 10% less volatile than the broader market.

Aptamer Group has higher revenue and earnings than 4D pharma. Aptamer Group is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
4D pharma	£718K	0.00	-£31.94M	-£15.40	N/A
Aptamer Group	£1.38M	9.38	-£14.17M	-£0.11	N/A

4D pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. 4D pharma's return on equity of -89.48% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
4D pharma	N/A	-89.48%	-42.64%
Aptamer Group	-178.52%	-135.35%	-44.96%

26.8% of 4D pharma shares are held by institutional investors. Comparatively, 3.3% of Aptamer Group shares are held by institutional investors. 12.2% of 4D pharma shares are held by company insiders. Comparatively, 7.3% of Aptamer Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

4D pharma beats Aptamer Group on 7 of the 11 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APTA vs. The Competition

Export

Metric	Aptamer Group	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£12.96M	£4.01B	£7.38B	£2.54B
Dividend Yield	N/A	3.64%	2.53%	6.17%
P/E Ratio	-3.40	11.62	272.60	367.57
Price / Sales	9.38	1,334.62	623.33	83,481.74
Price / Cash	N/A	105.14	78.62	27.89
Price / Book	1.75	16.80	13.05	7.19
Net Income	-£14.17M	-£12.50M	£3.47B	£5.89B
7 Day Performance	-6.50%	3.29%	2.09%	0.30%
1 Month Performance	-18.70%	8.23%	6.64%	3.31%
1 Year Performance	-47.18%	55.05%	25.02%	22.13%

Aptamer Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APTA Aptamer Group	N/A	GBX 0.37 +6.9%	N/A	-47.2%	£12.96M	£1.38M	N/A	37	News Coverage Gap Down
HVO hVIVO	N/A	GBX 6.70 +1.5%	GBX 15 +123.9%	-34.5%	£46.12M	£46.77M	N/A	N/A
HEMO Hemogenyx Pharmaceuticals	N/A	GBX 640 +5.3%	N/A	+241.0%	£43.52M	N/A	N/A	14
COIL Roquefort Therapeutics	N/A	GBX 10 +5.3%	N/A	-28.5%	£42.68M	N/A	N/A	9	Gap Down
C4XD C4X Discovery	N/A	N/A	N/A	N/A	£30.27M	£24.68M	300.00	49	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:APTA) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptamer Group (APTA) Competitors

APTA vs. HVO, HEMO, COIL, C4XD, and DDDD

How does Aptamer Group compare to hVIVO?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Summary

How does Aptamer Group compare to C4X Discovery?

Summary

How does Aptamer Group compare to 4D pharma?

Summary

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptamer Group (APTA) Competitors

APTA vs. HVO, HEMO, COIL, C4XD, and DDDD

How does Aptamer Group compare to hVIVO?

Which has more volatility & risk, HVO or APTA?

Does the media prefer HVO or APTA?

Is HVO or APTA more profitable?

Do insiders and institutionals believe in HVO or APTA?

Do analysts recommend HVO or APTA?

Which has better valuation & earnings, HVO or APTA?

Summary

How does Aptamer Group compare to Hemogenyx Pharmaceuticals?

Which has more volatility and risk, APTA or HEMO?

Do insiders and institutionals believe in APTA or HEMO?

Does the media refer more to APTA or HEMO?

Which has stronger valuation & earnings, APTA or HEMO?

Is APTA or HEMO more profitable?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Is APTA or COIL more profitable?

Do institutionals and insiders have more ownership in APTA or COIL?

Which has stronger valuation and earnings, APTA or COIL?

Does the media refer more to APTA or COIL?

Which has more volatility and risk, APTA or COIL?

Summary

How does Aptamer Group compare to C4X Discovery?

Is APTA or C4XD more profitable?

Which has preferable valuation & earnings, APTA or C4XD?

Which has more risk & volatility, APTA or C4XD?

Do institutionals & insiders believe in APTA or C4XD?

Does the media prefer APTA or C4XD?

Summary

How does Aptamer Group compare to 4D pharma?

Does the media refer more to DDDD or APTA?

Which has more risk & volatility, DDDD or APTA?

Which has better earnings & valuation, DDDD or APTA?

Is DDDD or APTA more profitable?

Do institutionals & insiders believe in DDDD or APTA?

Summary

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools